It’s a particularly exciting time for the stem cell field. One of the most notable developments in the last year or so is the production and preliminary study of a totally new type of human embryonic stem cells (ESC) made by nuclear transfer instead of using leftover in vitro fertilization (IVF) embryos. This process of so-called […]
Dieter Egli Interview: NT-ES cells, IPSC, Mitochondrial Transfer, & More Read More »
Advances in therapeutic cloning reported in the past year have been very exciting as somatic cell nuclear transfer (SCNT) can be used to produce very powerful human embryonic stem cells (ESC). These new cells are called NT-ESCs for short. Neither embryos nor reprogramming factors are needed to produce human NT-ESCs. See here, here and here for discussions of the pioneering papers reporting creation of
Future of Somatic Cell Nuclear Transfer to make ES Cells Read More »
With more than 4,142 votes cast, the readers of this blog have chosen the top 12 finalists for the Stem Cell Person of the Year Award for 2014 from the 27 nominees. You can see the final vote tallies at left. The votes came from more than 50 countries with some interesting geographic patterns (I
Diverse Stem Cell Person of the Year 2014 Award Finalists Read More »
With one week left to vote to pick the top 12 finalists for the Stem Cell Person of the Year 2014 Award, we have more than 2,800 votes in so far. From the top 12 vote-getters, I will choose the winner. This is the third year of this award. I self-fund this award out of
Stem Cell Person of the Year Award 2014 Voting: Who Will Be Finalists? Read More »
The stem cell biotech Advanced Cell Technology (ACT) reported new, positive data in a paper in Lancet from their clinical trials using retinal pigmented epithelial cells (RPEs) made from human embryonic stem cells (hESC) for treatment of different forms of macular degeneration (MD). The paper was entitled “Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related
Advanced Cell Technology pub: Trial for Macular Degeneration Read More »
There has been considerable discussion about the whether the media hyped the recent Harvard stem cells for diabetes paper (see top 10 takeaways of that paper). I believe that this was greatly hyped. This Harvard publication reported production of insulin-secreting cells from human embryonic stem cells (hESC). Newspapers around the world widely exaggerated the potential impact
Stem cells for Diabetes: the danger of the word ‘cure’ Read More »
The idea of using stem cells for treat Type I Diabetes is very promising and could have huge practical impact. Real progress has been achieved toward this goal over the last decade. In perhaps another decade there might be a validated treatment. A new stem cell paper has just come out in Cell from Harvard in this
Takeaways From Harvard Stem Cells for Diabetes Paper Read More »
Nominations have closed and we have more than two dozen nominations for Stem Cell Person of the Year 2014. It’s an exciting, diverse group including some news faces as well as nominees from years past as well. Happy Stem Cell Day! You can now vote for your choice for the top finalists in the poll
Stem Cell Person of the Year 2014 Award: Vote To Choose 12 Finalists Read More »
Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based
BioTime Cell Cure Files IND with FDA for ES cell AMD therapy Read More »
How do “drugs” influence stem cells? Here’s the straight dope. Those of us in the trenches of the stem cell research field spend an inordinate amount of time talking about stem cell treatments (i.e. you inject stem cells into a person hoping for a medical benefit), and far too little time discussing endogenous stem cells.
These are your stem cells on drugs…any questions? Read More »